PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2172250
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2172250
Drug Discovery Informatics market size was valued at US$ 4,230.9 Million in 2025, expanding at a CAGR of 10.9% from 2026 to 2033.
Drug discovery informatics is the use of various software and computational-based techniques to help speed up drug discovery. It involves the combination of different scientific disciplines, such as chemistry and biology, along with IT, in order to assist in handling large volumes of data. In this way, tasks such as molecular modeling, virtual screening, compound library management, and predictive toxicology can be done. It helps the researcher to make informed decisions using the data, facilitating the identification of drug candidates in less time with reduced costs.
The whole process requires the use of complicated technology, including artificial intelligence and machine learning, in order to recognize data patterns. It plays an important part in ensuring that pharmaceutical research moves into the modern era in terms of time frame. Hence, drug discovery informatics speeds up pharmaceutical innovation by improving data management, analysis, and decision-making.
Drug Discovery Informatics Market- Market Dynamics
Advancements In Personalized Medicine To Drive Market Demand
Advancements in personalized medicine are driving growth in the Drug Discovery Informatics market due to the increasing adoption of patient-centric treatment options and increased adoption of tools for analysis of genomic and clinical data. The advanced informatics can aid in finding new targets and drug efficacy and can lead to the development of better therapies. For instance, in January 2026, according to the World Economic Forum's Org Global Cybersecurity Outlook 2026, 64% of organizations have accounted for cyberattacks motivated by geopolitical reasons, which involve targeting critical infrastructure and espionage. Nation-states are utilizing advanced cyber technology to attack the telecommunications industry of the US. Just 31% of those who were asked had confidence that their state could cope with major cyber incidents compared to 26% in the previous year. This indicates how important it is to increase preparedness for cyber threats.
The Global Drug Discovery Informatics market is segmented on the basis of Service, Application, Solution, End Use, and Region.
Under Service Outlook, Sequence Analysis Platforms hold a key role in the Drug Discovery Informatics market, as they offer researchers capabilities to analyze DNA, RNA, and protein sequences for discovering drug targets and developing drugs. In January 2025, Illumina, Inc. partnered with NVIDIA to combine genomic sequencing, multiomics, and artificial intelligence (AI) technologies to facilitate the interpretation of biological data. This means that advanced sequencing platforms are helping to discover new drug targets.
Drug Discovery Informatics Market- Geographical Insights
North America holds a leading position in the global Drug Discovery Informatics market because of increasing investments made towards R&D in the pharmaceutical industry and advancements in data mining and analysis techniques. For example, in March 2026, according to Statistics Canada (Gov), the Canadian R&D pharmaceutical industry reported R&D expenditure from US$1,998 million to US$2,590 million, compared to US$1,850 million to US$2,368 million. In-house R&D expenditures grew by 9.0% to reach US$1,480 million, the highest since the series started. The amount accounted for 5.7% of business R&D expenditure in Canada. This shows that there is an increase in investment into pharmaceutical research and development, supporting drug discovery and innovation across Canada.
Leading players operating in the global Drug Discovery Informatics market include Infosys Limited, Charles River Laboratories International, Inc., Collaborative Drug Discovery, Inc., Eurofins Scientific SE, and Jubilant Biosys Limited. All the above-mentioned players focus on utilizing informatics technology, data analytics, and digital tools to facilitate the process of drug discovery. In September 2026, Wacker Chemie AG launched a new liquid silicone rubber, which is called liquid silicone rubber, ELASTOSIL LR 5471. This material has the capacity to adhere itself and doesn't need additional curing. The material can be used for over-molding parts and rigid-soft assemblies. As, market players drive efficiency in drug discovery through advanced informatics and digital innovation.
In July 2026, Schrodinger introduced Bunsen, an AI co-scientist, to accelerate molecular discovery. It has received additional compute and technology infrastructure support from NVIDIA and Google Cloud.
In June 2025, Accenture announced an agreement to acquire SIPAL's Integrated Product Support business in Italy. The acquisition was completed in September 2025 and will extend Accenture's engineering capabilities to better serve the aerospace and defense sector.
In June 2025, Oracle launched its Defense Ecosystem, providing a network to help defense technology businesses leverage the benefits of the cloud and AI.